Status:
UNKNOWN
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Lead Sponsor:
Sheba Medical Center
Conditions:
Cutaneous Leishmaniasis
Eligibility:
All Genders
18-80 years
Brief Summary
Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin. One of the local treatment available ...
Detailed Description
Cutaneous leishmaniasis is usually treated by topical intervention. In more severe cases intralesional Pentostam injection may be applied. This treatment is extremely efficient but painful, however wi...
Eligibility Criteria
Inclusion
- Cutaneous leishmaniasis patients
- Treatment by IL Pentostam
- Age above 18 years
Exclusion
- Children and pregnant women will not participate in the study
Key Trial Info
Start Date :
November 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02281669
Start Date
November 1 2014
End Date
January 1 2017
Last Update
November 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center of Geographic Medicine
Tel Litwinsky, Israel